Daniel Benzecry de Almeida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Benzecry de Almeida has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Afonso Henrique Aragao
Instituto de Neurologia de Curitiba, Neurocirurgia,Curitiba, Parana, Brazil
1 shared publication- Arlindo Nascimento de Lemos Junior
Faculdade de Medicina São Leopoldo Mandic, Brasil
1 shared publication - Joel Sanabria Duarte
Department of Neurosurgery, NeuroDOC, Curitiba, Brazil
1 shared publication - João Augusto Nocera Paulin
Hospital Nossa Senhora das Graças, Brasil
1 shared publication - Marcelo de Paula Loureiro
Universidade Positivo, Brazil
1 shared publication - Pietro Maran Novais
Universidade Positivo, Brasil
1 shared publication
Latest Publications
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 22, e20220095
Endoscopic lumbar sympathectomy as a treatment option for primary erythromelalgia - case report and review
Erythromelalgia is a rare disease, involving pain, edema, redness, and hyperthermia in the limbs. It is extremely refractory to drugs, has no defined treatment, and causes psychological comorbidities in the patient. We describe a case of erythromelalgia involving a 17-year-old boy who had been suffering from the disease for almost 4 years prior to finding an effective treatment. A bilateral endoscopic lumbar sympathectomy was performed, limited to L2 and L3 resections. Four weeks after the procedure, the patient’s symptoms were significantly mitigated and at 8 months follow-up he remained almost asymptomatic. Endoscopic lumbar sympathectomy was an effective treatment for primary erythromelalgia in this teenager, with exceptional reduction of his symptoms.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 22, e20220095
Open AccessEndoscopic lumbar sympathectomy as a treatment option for primary erythromelalgia - case report and review
Erythromelalgia is a rare disease, involving pain, edema, redness, and hyperthermia in the limbs. It is extremely refractory to drugs, has no defined treatment, and causes psychological comorbidities in the patient. We describe a case of erythromelalgia involving a 17-year-old boy who had been suffering from the disease for almost 4 years prior to finding an effective treatment. A bilateral endoscopic lumbar sympathectomy was performed, limited to L2 and L3 resections. Four weeks after the procedure, the patient’s symptoms were significantly mitigated and at 8 months follow-up he remained almost asymptomatic. Endoscopic lumbar sympathectomy was an effective treatment for primary erythromelalgia in this teenager, with exceptional reduction of his symptoms.
- Open Access
- 30 September 2020
- Published by Headache Medicine in Headache Medicine
- Vol. 11 (3) , 61-67
CGRP: from history to clinical application - A review
The role of calcitonin gene-related peptide (CGRP) and its receptor have played an important role in migraine for the last decades due to development of therapies that target their receptors at the trigeminal pain system, aiming at prevention or relief of acute migraine attacks. At first, CGRP receptor antagonists, called gepants have demonstrated appropriate effectiveness. In addition, they did not cause vasoconstriction, one of the drawbacks of triptans. However, their use had to be discontinued due to the risk of liver toxicity. Humanized monoclonal antibodies towards CGRP and the CGRP receptor have been developed as an alternative approach to block CGRP transmission. Still, there are some questions not fully answered as where CGRP and its receptor are located, how they influence the mechanisms of migraine attacks and if the blood brain barrier has any sort of importance. There is still much to learn about CGRP and migraine pathophysiology, especially its anatomical target sites and anti-CGRP agents. This paper presents a review of CGRP, including a brief history, focusing in CGRP mechanism, updates and future treatments.
- 30 September 2020
- Published by Headache Medicine in Headache Medicine
- Vol. 11 (3) , 61-67
Open AccessCGRP: from history to clinical application - A review
The role of calcitonin gene-related peptide (CGRP) and its receptor have played an important role in migraine for the last decades due to development of therapies that target their receptors at the trigeminal pain system, aiming at prevention or relief of acute migraine attacks. At first, CGRP receptor antagonists, called gepants have demonstrated appropriate effectiveness. In addition, they did not cause vasoconstriction, one of the drawbacks of triptans. However, their use had to be discontinued due to the risk of liver toxicity. Humanized monoclonal antibodies towards CGRP and the CGRP receptor have been developed as an alternative approach to block CGRP transmission. Still, there are some questions not fully answered as where CGRP and its receptor are located, how they influence the mechanisms of migraine attacks and if the blood brain barrier has any sort of importance. There is still much to learn about CGRP and migraine pathophysiology, especially its anatomical target sites and anti-CGRP agents. This paper presents a review of CGRP, including a brief history, focusing in CGRP mechanism, updates and future treatments.